Everest Medicines focuses on in-licensing, developing and commercializing transformative pharmaceutical products for Greater China and Asian markets. The company has built a portfolio of eight potentially first-in-class or best-in-class molecules, with several programs in late-stage development and multiple assets in registrational or global Phase 3 trials. Key assets include Trodelvy (sacituzumab govitecan) with US approval and a CTA approval in China for mTNBC, Xerava (eravacycline) with US/EU approval and a Phase 3 trial in China, and late‑stage programs such as etrasimod, taniborbactam, ralinepag XR, nefecon, FGF401 and SPR206. Everest plans to use proceeds from its financing to advance clinical development across its pipeline and to build commercial infrastructure for the next phase of growth. The company was incubated by CBC Group and has publicly noted rapid progress since its inception in late 2017.

Total raised

$310M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2020